NZ597830A - Methods and compositions for treating cancer comprising abiraterone acetate and prednisone - Google Patents

Methods and compositions for treating cancer comprising abiraterone acetate and prednisone

Info

Publication number
NZ597830A
NZ597830A NZ597830A NZ59783007A NZ597830A NZ 597830 A NZ597830 A NZ 597830A NZ 597830 A NZ597830 A NZ 597830A NZ 59783007 A NZ59783007 A NZ 59783007A NZ 597830 A NZ597830 A NZ 597830A
Authority
NZ
New Zealand
Prior art keywords
day
abiraterone acetate
prednisone
specifically
compositions
Prior art date
Application number
NZ597830A
Other languages
English (en)
Inventor
Alan H Auerbach
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ597830(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of NZ597830A publication Critical patent/NZ597830A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ597830A 2006-08-25 2007-08-23 Methods and compositions for treating cancer comprising abiraterone acetate and prednisone NZ597830A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
NZ597830A true NZ597830A (en) 2013-02-22

Family

ID=38916904

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597830A NZ597830A (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer comprising abiraterone acetate and prednisone

Country Status (20)

Country Link
EP (3) EP3804730A1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20180003636A (enExample)
CN (2) CN101528308A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2061561T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2478907T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2478907T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
MX2010004405A (es) * 2007-10-29 2010-05-03 Takeda Pharmaceutical Derivados de pirrolo [1,2-c] imidazol para utilizarse en la profilaxis o tratamiento de cancer que es refractario a terapias cancerigenas conocidas.
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG10201600077RA (en) 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
BR112014030099A2 (pt) * 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR20160023641A (ko) * 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
CN108472242A (zh) * 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
BR112016006970A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
CN109674801A (zh) * 2013-10-01 2019-04-26 诺华股份有限公司 组合
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3280448B1 (en) * 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
IL322013A (en) 2016-07-29 2025-09-01 Janssen Pharmaceutica Nv Niraparib or its salts for use in the treatment of prostate cancer
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
EP4135659A1 (en) * 2020-04-16 2023-02-22 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633893T3 (da) 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1583539A2 (en) * 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物

Also Published As

Publication number Publication date
KR20200125776A (ko) 2020-11-04
RS52956B (sr) 2014-02-28
DK2478907T3 (da) 2021-05-25
JP6053279B2 (ja) 2016-12-27
JP2018065859A (ja) 2018-04-26
EP2478907B1 (en) 2021-04-14
JP2020114851A (ja) 2020-07-30
AU2015221447B2 (en) 2016-12-15
AU2022206696A1 (en) 2022-08-11
AU2007287098C1 (en) 2018-03-15
SI2478907T1 (sl) 2021-08-31
AU2017201764A1 (en) 2017-04-06
EP3804730A1 (en) 2021-04-14
JP2017052791A (ja) 2017-03-16
AU2018271331A1 (en) 2018-12-20
NO20091190L (no) 2009-03-20
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
JP6740497B2 (ja) 2020-08-12
PT2061561E (pt) 2013-10-09
ES2428634T3 (es) 2013-11-08
JP2010501575A (ja) 2010-01-21
JP6445123B2 (ja) 2018-12-26
CY1124221T1 (el) 2022-05-27
HK1131577A1 (en) 2010-01-29
JP2015110577A (ja) 2015-06-18
KR20150108946A (ko) 2015-09-30
SI2061561T1 (sl) 2013-11-29
AU2015221447B9 (en) 2017-07-20
JP2022185091A (ja) 2022-12-13
WO2008024484A1 (en) 2008-02-28
EP2478907A3 (en) 2012-08-01
IL227746A0 (en) 2013-09-30
CA2661422A1 (en) 2008-02-28
DK2061561T3 (da) 2013-10-07
CA2661422C (en) 2017-06-27
CY1115477T1 (el) 2017-01-04
CN101528308A (zh) 2009-09-09
HRP20130961T1 (hr) 2013-11-22
LT2478907T (lt) 2021-06-25
JP2012082215A (ja) 2012-04-26
HRP20210670T1 (hr) 2021-06-11
PL2061561T3 (pl) 2013-12-31
CN104306977A (zh) 2015-01-28
EP2061561A1 (en) 2009-05-27
AU2007287098B2 (en) 2013-08-15
IL257681A (en) 2018-04-30
PT2478907T (pt) 2021-05-26
JP2021038252A (ja) 2021-03-11
EP2478907A2 (en) 2012-07-25
NO20200775A1 (no) 2009-03-20
IL197211A0 (en) 2009-12-24
KR20180003636A (ko) 2018-01-09
AU2015221447A1 (en) 2015-09-17
RS62034B1 (sr) 2021-07-30
JP2024164147A (ja) 2024-11-26
JP2019059750A (ja) 2019-04-18
AU2007287098A1 (en) 2008-02-28
HUE054495T2 (hu) 2021-09-28
ES2869343T3 (es) 2021-10-25
KR20090059126A (ko) 2009-06-10
PL2478907T3 (pl) 2021-10-25

Similar Documents

Publication Publication Date Title
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
WO2012079092A3 (en) Testosterone undecanoate compositions
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MA30290B1 (fr) Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
SI1819227T1 (sl) Farmacevtska formulacija decitabina
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
IN2014MN00139A (enExample)
JP2009545600A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2006516571A5 (enExample)
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
HRP20151091T1 (hr) UPORABA 24-norUDCA
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 AUG 2014 BY CPA GLOBAL

Effective date: 20130801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 AUG 2017 BY CPA GLOBAL

Effective date: 20140710

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 AUG 2020 BY CPA GLOBAL

Effective date: 20140906

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 AUG 2021 BY CPA GLOBAL

Effective date: 20200709

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 AUG 2022 BY CPA GLOBAL

Effective date: 20210708

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 AUG 2023 BY CPA GLOBAL

Effective date: 20220707

LAPS Patent lapsed